Physician profile
Rawaa M Almukhtar
NPI 1003202409
$57,177.25
in general payments reported to CMS, 2019-2025
43 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $172 · 2021: $503 · 2022: $458 · 2023: $3,908 · 2024: $11K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $31K · Food and Beverage: $16K · Consulting Fee: $5,375 · Travel and Lodging: $2,274 · Education: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $30,700.00 |
| Food and Beverage | $15,945.24 |
| Consulting Fee | $5,375.00 |
| Travel and Lodging | $2,273.74 |
| Education | $578.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $31,763.19 | 2025 | Vtama |
| Janssen Biotech, INC. | $5,014.90 | 2022-2025 | Tremfya |
| Incyte Corporation | $4,288.23 | 2022-2025 | Opzelura |
| Parapro, LLC | $2,500.00 | 2024 | Natroba |
| Abbvie INC. | $1,388.11 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $1,355.88 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $1,354.56 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $1,266.09 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $1,102.21 | 2023-2025 | Ilumya |
| Dermavant Sciences, INC. | $873.99 | 2023-2024 | Vtama |
| Leo Pharma INC. | $688.47 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $664.15 | 2022-2025 | |
| Ucb, INC. | $624.86 | 2024-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $605.19 | 2023-2025 | Zoryve |
| Amgen INC. | $527.70 | 2019-2025 | Otezla, Otezla |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rawaa Almukhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.